Hot Tech Stocks To Invest In Right Now

We continue to track the short interest changes in the primary 3D printer and services companies. The following information is based on data reported on December 24 for the period that ended December 13.

Short interest in 3D Systems Corp. (NYSE: DDD) fell 2.3% to 16.17 million shares. Some 16.7% of the company’s stock is short. In the two-week short interest period to December 13, shares rose about 8.2% and are up about 148% for the year to date, as of Thursday night. The stock’s 52-week range is $27.88 to $92.68. The high was posted Thursday.

Short interest in Proto Labs Inc. (NYSE: PRLB) increased by 6.6% to 3.03 million shares, or 14.6% of the company’s float. Shares were down about 8.5% in the two-week period and closed Thursday at $71.93, up about 84% year to date. The stock’s 52-week range is $35.86 to $89.97.

Stratasys Ltd. (NASDAQ: SSYS) saw short interest drop 2.9% in the first two weeks of December to 1.9 million shares, or about 5.1% of the company’s float. Shares rose about 1.2% in the two-week period and closed at $130.33 Thursday, up about 60% for the year. The stock’s 52-week range is $60.20 to $134.00.

Hot Tech Stocks To Invest In Right Now: Lionbridge Technologies Inc.(LIOX)

Lionbridge Technologies, Inc. provides language, development, and testing services. Its Global Language and Content segment provides product localization services, such as creating foreign language versions of its clients? products and software applications, including the user interface, online help systems, and documentation; and content translation services, such as translating and maintaining clients? Web-based content, eLearning courseware and training materials, technical support, and sales and marketing information. It also offers technical authoring, eLearning courseware development, and production and integration of content; and global language and content services delivery. The company?s Global Development and Testing segment develops and maintains on-premise, SaaS, and smart phone and tablet applications, as well as provides Web production services. This segment also offers various testing services under the VeriTest brand, including managed test teams, test proc ess design, test automation, functional testing, performance testing, globalization testing, and product certification. In addition, it provides specialized search relevance, online content editorial, keyword optimization, and related services. Its Interpretation segment offers interpretation services for government business and healthcare organizations that require experienced linguists to facilitate communication. It provides interpretation communication services, such as onsite interpretation, over-the-phone interpretation and interpreter testing, training, and assessment services in approximately 360 languages and dialects. The company serves the technology, mobile and telecommunications, Internet and media, life sciences, government, manufacturing, automotive, retail, and aerospace sectors in the Americas, Europe, and Asia. Lionbridge Technologies, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Advisors’ Opinion:

  • [By Jeff Reeves]

    Lionbridge (LIOX) is the kind of cheap, small-cap stock that investors love. This player has soared 60% in the last three months thanks to nice earnings and improving investor sentiment.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Lionbridge Technologies (Nasdaq: LIOX  ) , whose recent revenue and earnings are plotted below.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Lionbridge Technologies (Nasdaq: LIOX  ) , whose recent revenue and earnings are plotted below.

Hot Tech Stocks To Invest In Right Now: Chromadex Corp (CDXC)

Chromadex Corporation, incorporated on June 19, 2008, is a provider of research and quality-control products and services to the natural products industry. The Company’s products are used by customers worldwide in the dietary supplement, food and beverage, cosmetic and pharmaceutical industries. The Company together with its subsidiaries supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of potential attributes, and reference materials, related contract services, technical consulting and ingredients. On December 3, 2012, ChromaDex Inc. acquired Spherix Consulting Inc. The Company’s principal subsidiaries include ChromaDex, Inc., Chromadex Analytics, Inc. and Spherix Consulting, Inc (Spherix).

The Company provides its clients in the food, supplement and pharmaceutical industries with solutions to manage potential health and regulatory risks. Its science-based solutions are for both new and existing products that may be subject to product liability and/or exposed to changing scientific standards or public perceptions; literature evaluations, and design and assessment of pre-clinical and clinical safety testing. It specializes in regulatory submissions for food and dietary supplement ingredients. For its clients involved in drug development within the pharmaceutical industry, the Company provides similar services, as well as risk-based strategies, including intellectual property data and compliance gap identification, due diligence assessments and investigational new drug writing.

Products and Services

The Company offers bulk raw materials for inclusion in dietary supplements, food, beverage and cosmetic products. Through its catalog, it supplies a range of products necessary to conduct quality control of raw materials and consumer products. The Company through Chromadex Analytics, provides a range of contract services ranging from routine contract analysis for the production of dietary sup! plements, cosmetics, foods and other natural products to elaborate contract research for clients in these industries. The Company provides a range of consulting services in the areas of regulatory support, new ingredient or product development, risk management and litigation support. With an addition of Spherix, it provides regulatory approval and scientific advisory services.

The Company competes with Sigma-Aldrich, Phytolab, US Pharmacopoeia, Extrasynthese, Covance, Eurofins, and Silliker Canada Co.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap stocks Chromadex Corp (OTCMKTS: CDXC) and 22nd Century Group Inc (OTCBB: XXII) are, one way or the other, focused on natural products and have been getting some extra attention lately. Moreover, one of these stocks have been the subject of a disclosed investor awareness campaign. Keeping that in mind, are these two small cap stocks natural winners for investors? Here is a quick look:

Hot Tech Stocks To Invest In Right Now: Market Leader Inc(LEDR)

Market Leader, Inc., together with its subsidiaries, provides software-as-a-service-based business and marketing solutions for real estate professionals primarily in the United States and Canada. It offers real estate agents and brokerage companies with software-as-a-service based products, as well as online lead-generation, online prospect management, online real estate portal content and advertising, and customer coaching and training solutions. The company also offers consumers with free access to the information and tools they need throughout the home buying and selling process through its national consumer real estate sites. Its consumer Web sites include: JustListed.com, a service that notifies home buyers as soon as new homes hit the market; HouseValues.com, a service, which provides home sellers with market valuations of their current homes; and HomePages.com, a real estate portal that enables consumers to see the home listings in their area, view detailed neighbor hood and school data, compare recent home sales, find local real estate agents, and find the value of their own homes. In addition, the company offers Growth Leader, a Website and customer relationship management tool for real estate agents; RealtyGenerator, a lead-generation and lead management system for real estate brokerage offices; and ActiveRain.com that provides professional networking, referral, recruitment, content syndication, and online marketing services for professionals in real estate and related businesses. Market Leader, Inc. markets its products to individual agents and brokerage offices directly, as well as through marketing partnerships with real estate franchise networks. The company was formerly known as Housevalues, Inc. and changed its name to Market Leader, Inc. in November 2008. Market Leader, Inc. was founded in 1999 and is headquartered in Kirkland, Washington.

Advisors’ Opinion:

  • [By Michael Lewis]

    For a bit of context, competitor Trulia (NYSE: TRLA  ) is in negotiations to buy Market Leader (NASDAQ: LEDR  ) for $355 million. Market Leader is a smaller (and growing) business that’s similar to both Zillow and Trulia. Since Market Leader is still earnings negative, we can’t compare it on a P/FCF basis, but we can look at other metrics. For one, Market Leader trades at a still-ridiculous-but-slightly less-so 57.2 times forward earnings. It trades at 6.4 times last year’s sales. Zillow trades at 16.4 times last year’s sales. Management expects sales to hit (on the high end) $182 million — that implies a price of 10.55 times forward sales. If they double a year or two after, which would be unbelievably phenomenal, it would trade at 5.3 times sales.

Hot Tech Stocks To Invest In Right Now: Redpoint Bio Corp (RPBC)

Redpoint Bio Corporation (Redpoint), incorporated in August 1995, is a development-stage biotechnology company. The Company leverages discoveries in the molecular biology of taste to discover and develop taste modulators for the food and beverage industries. Its food and beverage program has been focused on identifying flavor modifiers that improve the taste of ingredients. In June 2009, the Company announced that it had identified an all-natural sweetness enhancer, RP44. RP44 is Reb-C (rebaudioside C), a component of the stevia plant.

Sweetness Enhancer Program

Redpoint announced that it had identified RP44, an all-natural sweetness enhancer, in June 2009. In January 2010, it disclosed that RP44 is Reb-C (rebaudioside C), a component of the stevia plant. RP44 is derived from material found in the side stream of the Reb A production process. A purified component of stevia known as Reb A has received regulatory approval in the United States. Unlik e Reb A, RP44 has a low intrinsic level of sweetness and therefore is not useful as a sweetener.

Diabetes and Obesity Drug Discovery Program

The Company’s initial programs focused on the modulation of the TRPm5 ion channel, a signaling element in taste sensation, in order to discover compounds that modulate the taste of food and beverage products. Redpoint initiated a program designed to leverage the research it had already conducted on the discovery of modulators of the TRPm5 ion channel to further explore opportunities for the discovery of diabetes or obesity therapeutics. TRPm5 modulators discovered at Redpoint have been shown to elicit the secretion of hormones known to play roles in metabolism in relevant model systems.

The Company competes with International Flavors & Fragrances Inc., Givaudan SA, Symrise, Firmenich, Senomyx, PureCircle Ltd, GLG Life Tech Corporation, Eli Lilly and Company, Amylin Pharmaceuticals, Merck & Co., Inc., Metabolex, Inc., OSI Pharmaceuticals, GlaxoSmithKline! , Arena Pharmaceuticals, Inc. and Johnson & Johnson.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check:

Hot Tech Stocks To Invest In Right Now: Infinera Corporation(INFN)

Infinera Corporation provides optical networking equipment, software, and services to communications service providers, Internet content providers, cable operators, and subsea network operators worldwide. Its products include digital transport node (DTN) platform that utilizes photonic integrated circuit technology to enable digital processing and management of data with the capability to generate wavelength division multiplexing (WDM) wavelengths and to add, drop, switch, manage, protect, and restore network traffic digitally; line systems that provide the management communications channel between network nodes and allow customers to manage capacity on network; and ATN platform that is used to extend the digital optical network architecture benefits of the DTN platform, and used as standalone WDM access systems. The company also provides IQ Network Operating System, an embedded software operating system that enables customers to simplify and speed up the tasks they perfor m to deliver, differentiate, and manage services; and a set of standards-based network and element management tools and operations support system integration interfaces to manage DTN and ATN platforms. In addition, it offers various product support services, including hardware and software technical support, installation and deployment, spares management, first line maintenance, on-site technical support, product technical training, and extended product warranties. The company?s customers include competitive carriers, multiple system operators, incumbent carriers, research and education/government organizations, and resellers. Infinera Corporation markets and sells its products and related support services primarily through its direct sales force, as well as through distribution or support partners. The company, formerly known as Zepton Networks, was founded in 2000 and is headquartered in Sunnyvale, California.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    Technology stocks gained Thursday, with Infinera (NASDAQ: INFN) leading advancers. Meanwhile, gainers in the sector included LiveDeal (NASDAQ: LIVE), with shares up 5.5 percent, and PFSweb (NASDAQ: PFSW), with shares up 5.4 percent.

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    Technology stocks gained Thursday, with Infinera (NASDAQ: INFN) leading advancers. Meanwhile, gainers in the sector included Envivio (NASDAQ: ENVI), with shares up 2.8 percent, and Adept Technology (NASDAQ: ADEP), with shares up 4.3 percent.

Hot Tech Stocks To Invest In Right Now: P.T. Telekomunikasi Indonesia Tbk.(TLK)

Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk provides telecommunication and network services worldwide. The company?s Fixed Wireline segment offers local, domestic long-distance, international telephone services, and other telecommunications services, including leased lines, telex, transponder, satellite, and very small aperture terminal (VSAT), as well as ancillary services. Its Fixed Wireless segment provides local and domestic long-distance code division multiple access-based telephone services, as well as other telecommunication services within a local area code. Perusahaan Perseroan?s Cellular segment offers mobile cellular telecommunication services. Its network services comprise satellite transponder leasing, satellite broadcasting, VSAT, audio distribution, and terrestrial and satellite-based leased lines. The company?s data and Internet services include short messaging service for fixed wire line, fixed wireless, and cellular phones, dial-up and broadband Internet access, virtual private network (VPN) frame relay, Internet protocol (IP) VPN, voice over IP for international calls, integrated services digital network connections, and other multimedia services. The company also provides information services, such as billing, directory assistance, and content services; and wireless application protocol, Web portal, ring back tones, voicemail, and building management services. In addition, it offers consultancy services, as well as constructs and maintains telecommunications facilities; interconnection services; telephone directory production services; and cable and pay television services. As of December 31, 2010, the company served 120.5 million customers, including 8.3 million fixed wireline telephone subscribers, 18.2 million fixed wireless telephone subscribers, and 94.0 million cellular telephone subscribers. Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk was founded in 1884 and is headquartered in Bandung, Indonesia.

Advisors’ Opinion:

  • [By GuruFocus]

    Telekomunikasi Indonesia (Persero) Tbk (TLK) Reached the 52-Week Low of $34.63

    The prices of Telekomunikasi Indonesia (Persero) Tbk (TLK) shares have declined to close to the 52-week low of $34.63, which is 33.3% off the 52-week high of $50.61. Telekomunikasi Indonesia (Persero) Tbk is owned by five Gurus we are tracking. Among them, two have added to their positions during the past quarter. Two reduced their positions.

  • [By GuruFocus]

    Telekomunikasi Indonesia (TLK) Reached the 52-Week Low of $34.35

    The prices of Telekomunikasi Indonesia (TLK) shares have declined to close to the 52-week low of $34.35, which is 33.3% off the 52-week high of $50.61. Telekomunikasi Indonesia is owned by five Gurus we are tracking. Among them, two have added to their positions during the past quarter. Two reduced their positions.

Hot Tech Stocks To Invest In Right Now: Sanmina-SCI Corporation(SANM)

Sanmina-SCI Corporation provides integrated electronics manufacturing services worldwide. It offers product design and engineering services, including initial development, detailed design, prototyping, validation, preproduction, and manufacturing design; volume manufacturing of complete systems, components, and subassemblies; final system assembly and testing services; direct order fulfillment and logistics services; and after-market product service and support services. The company also manufactures various system components and subassemblies consisting of printed circuit boards, printed circuit board assemblies, backplanes and backplane assemblies, enclosures, cable assemblies, precision machine components, optical components and modules, and memory modules. It provides its services to original equipment manufacturers primarily in the communication, enterprise computing and storage, multimedia, industrial and semiconductor capital equipment, defense and aerospace, medica l, clean technology, and automotive industries. The company was founded in 1980 and is based in San Jose, California.

Advisors’ Opinion:

  • [By Eric Volkman]

    After being in the red last quarter, Sanmina’s (NASDAQ: SANM  ) bottom line has swung into positive territory. In the company’s Q2 results, net sales amounted to $1.43 billion, down from the $1.46 billion in the same period the previous year. The bottom line came in at $21.2 million ($0.25 per diluted share) from Q2 2012’s net loss of $1.4 million ($0.02) according to GAAP standards.

  • [By Seth Jayson]

    Sanmina (Nasdaq: SANM  ) reported earnings on April 22. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 30 (Q2), Sanmina met expectations on revenues and beat expectations on earnings per share.

  • [By Evan Niu, CFA]

    What: Shares of Sanmina (NASDAQ: SANM  ) have popped today by as much as 16% after the company reported earnings.

    So what: Revenue in the fiscal second quarter was $1.43 billion, and non-GAAP earnings per share came in at $0.30. That top-line result was in line with consensus estimates while the bottom-line was a beat relative to estimates. CEO Jure Sola said the company continues to face a “soft market environment” but that Sanmina continues to invest in technology and services, with new program ramps on the horizon.

Hot Tech Stocks To Invest In Right Now: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 – a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line trea tment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.

  • [By John Udovich]

    On Wednesday, small cap cancer stock Clovis Oncology Inc (NASDAQ: CLVS) soared 16.68% after announcing a $200 million cancer deal plus the biotech has more than tripled since late 2011, meaning it might be time to take a closer look at what’s driving the stock higher as well as look at the performance of biotech ETF benchmarks like iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).

  • [By John Udovich]

    Bubble talk, biotech IPO setbacks plus news about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

    Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron’s where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech IPO Setbacks. FierceBiotech has summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia, slashed its asking price on 6.9 million shares to $12 a share to raise $82 million from a range of $16 to $19 a share while Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its new, patient-friendly approach for delivering inhaled nitric oxide on the

  • [By Sean Williams]

    What: Shares of Clovis Oncology (NASDAQ: CLVS  ) , a biopharmaceutical company that’s developing anti-cancer therapies, vaulted higher by as much as 136% (that’s not a typo!) after reporting positive data on two early stage experimental treatments — CO-1686 in EGFR-mutant non-small cell lung cancer (NSCLC) and Rucaparib in a monotherapy study of solid tumors — at the American Society of Clinical Oncology’s annual meeting.

Hot Tech Stocks To Invest In Right Now: Responsys Inc.(MKTG)

Responsys, Inc. provides on-demand software and professional services primarily in North America, the Asia Pacific, and Europe. The company offers Responsys Interact suite, a software-as-a-service platform that provides marketers with a set of integrated applications to create, execute, optimize, and automate marketing campaigns in various channels, including email, mobile, social, and the Web. Its platform also leverages third-party applications and data from real-time sources allowing customers to deliver targeted content to its customers and known prospects as part of their interactive marketing campaigns. In addition, it provides professional services, such as strategic, creative, deliverability, campaign, and education services. The company offers its on-demand software and professional services to retail and consumer, travel, financial services, and technology industries through a direct sales force. Responsys, Inc. was founded in 1998 and is headquartered in San Bru no, California.

Advisors’ Opinion:

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Responsys (Nasdaq: MKTG  ) , whose recent revenue and earnings are plotted below.

  • [By The GeoTeam]

    Our recent 2013 articles on SaaS companies Selectica (SLTC), E2open (EOPN), Responsys (MKTG), Vocus (VOCS), and ExactTarget (ET) highlighted such opportunities. The average return since the inception of our coverage currently stands at around 34% (55% at their highs).